Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
TRIENTINE WAYMADE (Waymade Australia Pty Limited)
Product name
TRIENTINE WAYMADE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
188 (255 working days)
Active ingredients
trientine dihydrochloride
Registration type
NCE/NBE
Indication
TRIENTINE WAYMADE (capsule) is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.